The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Pastan, Ira H.
Wei, Junxia
Onda, Masanori
Bera, Tapan
Ho, Mitchell
Abstract
Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 14/21 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
2.
METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Lu, Yong-Chen
Fitzgerald, Peter
Zheng, Zhili
Rosenberg, Steven A.
Abstract
Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Khristov, Vladimir R.
Charles, Steven T.
Amaral, Juan A.
Maminishkis, Arvydas
Bharti, Kapil
Abstract
A surgical clamp for aligning the margins of incised or wounded tissue has jaws with parallel clamping faces, and a handle for manipulating the clamp to align the margins of the tissue. The jaws are in a normally closed position, however they can be opened by compressing the handle to open the jaws. Prongs project from the inferior surface of the jaws. The clamp is positioned in a desired position over the margins of a wound to be closed, the prongs engage the margins of the wound to be aligned, and the jaws are closed by releasing compressive force on the handle. As the jaws close the prongs help move the tissue into alignment. Suture guide slots through the jaws assist in the placement of precisely placed sutures across the incision. The disclosed surgical clamp is particularly suited for selectively closing and reopening surgical incisions, such as a sclerotomy incision in the eye. Methods are disclosed for using the clamp during intraocular and other surgical or minimally invasive procedures. In one example the clamp is used during implantation into the retina of a scaffold on which choroid and retinal pigment epithelium cells and retina grow in a three-dimensional matrix that mimics the native structure of the retina.
A61B 17/04 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for suturing wounds; Holders or packages for needles or suture materials
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Orentas, Rimas J.
Pastan, Ira H.
Dimitrov, Dimiter S.
Mackall, Crystal L.
Abstract
The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Orentas, Rimas J.
Pastan, Ira H.
Dimitrov, Dimiter S.
Mackall, Crystal L.
Abstract
The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
6.
SURGICAL TOOL AND METHOD FOR SOFT OCULAR TISSUE TRANSPLANTATION
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Maminishkis, Arvydas
Abstract
Disclosed are devices and methods for delivering a sheet of tissue into the eye in such a way that damage to the tissue is minimized, damage to the eye during insertion and manipulation of the tissue is minimized, and the tissue is released and delivered in a precise and controlled fashion.
A61F 9/00 - Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
7.
ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Love, Paul E.
Gaud, Guillaume
Hinrichs, Christian S.
Davies, John S.
Abstract
Disclosed is a cell expressing a modified CD3 subunit chain or a cell expressing a modified non-CD3 subunit chain comprising one or more of: (a) at least one Immuno-receptor Tyrosine-based Activation Motif (ITAM) deletion; or (b) at least one exogenous intracellular hematopoietic cell signaling domain; and (c) at least one modified ITAM comprising an amino acid sequence of Formula I. Related populations of cells, pharmaceutical compositions, methods of making the cells, methods of treating or preventing a condition in a subject, and methods of enhancing an antigen-specific immune response in a subject are also disclosed.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Tolia, Niraj H.
Ma, Rui
Duffy, Patrick E.
Renn, Jonathan P.
Abstract
The disclosure provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum. Aspects of the disclosed immunogen polypeptides comprise all or portions of the CSA binding regions of VAR2CSA as identified by a structural study of VAR2CSA conducted by the inventors. Also provided are compositions comprising such immunogen polypeptides, and methods of using the immunogen polypeptides for vaccination and treatment of disease.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
O'Keefe, Barry R.
Haugh Krumpe, Lauren R.
Pommier, Yves
Marchand, Christophe R.
Schroeder, Ingrid C.
Rosengren, K. Johan
Wilson, Brice A.P.
Abstract
Disclosed is a class of knotted cyclic peptides. Related pharmaceutical compositions and methods of using the peptides and methods of synthesizing the peptides are also disclosed.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Bulea, Thomas
Lerner, Zachary
Damiano, Diane
Gravunder, Andrew
Abstract
Disclosed are powered gait assistance systems that include a controller, sensors, and a torque applicator (motor, spring, etc.) coupled to a patient's hips, thighs, knee, lower leg, ankle, and/or foot and operable to apply assistive torque to the patient's leg joint(s) to assist the patient's volitional joint actuating muscle output during selected stages of the patient's gait cycle, such that the applied torque improves the patient's leg posture, muscle output, range of motion, and/or other parameters over the gait cycle. The sensors can include a torque sensor that measures torque applied, one or more joint angle sensors, a ground contact sensor that measures ground contact of the patient's foot, and/or other sensors. The controller can determine what stage of the patient's gait cycle the patient's leg is in based on sensor signals and cause the torque applicator to apply corresponding torque to the joint(s) based on the gait cycle stage, sensor inputs, and known patient characteristics.
A63F 13/212 - Input arrangements for video game devices characterised by their sensors, purposes or types using sensors worn by the player, e.g. for measuring heart beat or leg activity
A61H 1/02 - Stretching or bending apparatus for exercising
A61H 3/00 - Appliances for aiding patients or disabled persons to walk about
12.
NOVEL ADENO-ASSOCIATED VIRAL (AAV) VECTORS TO TREAT HEREDITARY METHYLMALONIC ACIDEMIA (MMA) CAUSED BY METHYLMALONYL-COA MUTASE (MMUT) DEFICIENCY
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Venditti, Charles P.
Chandler, Randy
Abstract
The present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV) and methods of using such vectors and viruses in gene therapy for treating methylmalonic acidemia in patients with methylmalonyl-coA mutase (MVMUT) deficiency. Also provided are pharmaceutical compositions comprising recombinant adeno-associated virus (rAAV) and a pharmaceutically acceptable carrier or excipient.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Lee, Kyung S.
Jacobson, Kenneth A.
Alverez, Celeste N.
Park, Jung-Eun
Oliva, Paola
Lee, Hobin
Pongorne Kirsch, Klara
Abstract
Provided is a method of treating cancer, particularly cancers associated with an overexpression of polo-like kinase (Plk1), comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof in which ring A, X1, X2, X3, X4, X5, R2, R3, R4, n, bond a, and bond b are described herein. Exemplary compounds of formula (I) and pharmaceutically acceptable salts thereof, especially those that selectively inhibit the polo box domain of Plk1, also are provided.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
14.
INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Desai, Sanjay A.
Pillai, Ajay D.
Abstract
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I,
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I,
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I,
or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4741 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Kim, Sanghyun
Zacharakis, Nikolaos
Rosenberg, Steven A.
Abstract
Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53R273C or human p53Y220C. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Ishii, Kazusa
Hinrichs, Christian S.
Abstract
Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a CD20 amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Gros, Alena
Rosenberg, Steven A.
Abstract
Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Parchment, Ralph E.
Nguyen, Thu A.
Abstract
Provided are inserts (100) for preparing a cell culture chamber(s), or array of chambers, inside of histology cassettes that are suitable for three-dimensional multicellular growth of a cell or cells into spheroids, organoids, or other 3D structures, such that the resulting 3D multi-cellular structures are ready and suitable for histology processing without transfer to a different receptacle or container. Further embodiments of the invention provide methods of preparing at least one cell culture chamber using the inserts, systems for growing three-dimensional multicellular spheroids comprising culturing cells within a cell culture chamber prepared using the inserts, and systems for analyzing at least one cultured cell in vitro comprising culturing cells within a cell culture chamber prepared using the inserts.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Schlom, Jeffrey
Hamilton, Duane H.
Palena, Claudia M.
Donahue, Renee N.
Abstract
The invention provides human immunogenic epitopes of HEMO and HHLA2 human endogenous retroviruses (HERVs), which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Levin, Noam
Yoseph, Rami
Cafri, Gal
Rosenberg, Steven A.
Abstract
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid. The TCRs may recognize G12D RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Beaucage, Serge L.
Grajkowski, Andrzej M.
Abstract
Disclosed herein are embodiments of a solid support suitable for synthesizing nucleic acid sequences. The solid support may have a structure according to Formula I, where CPG is controlled pore glass, and m, n, x, y, R1 and R2 are as defined herein.
Disclosed herein are embodiments of a solid support suitable for synthesizing nucleic acid sequences. The solid support may have a structure according to Formula I, where CPG is controlled pore glass, and m, n, x, y, R1 and R2 are as defined herein.
Disclosed herein are embodiments of a solid support suitable for synthesizing nucleic acid sequences. The solid support may have a structure according to Formula I, where CPG is controlled pore glass, and m, n, x, y, R1 and R2 are as defined herein.
Also disclosed are methods for making and using the solid support, kits including solid support, and a universal linker phosphoramidite suitable for use in the solid support.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C40B 50/18 - Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support using a particular method of attachment to the solid support
22.
METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR-REACTIVE T CELLS FROM TUMOR
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Gros, Alena
Rosenberg, Steven A.
Abstract
Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8+ T cells that express any one or more of TIM-3, LAG-3, 4-1BB, and PD-1 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (USA)
Inventor
Kulam Najmudeen, Magdoom Mohamed
Basser, Peter J.
Komlosh, Michal E.
Abstract
Diffusion sensitizing gradient pulse pairs are prescribed in a manner to mitigate effects of concomitant gradient artifacts. Measured MR signals generated by applying a plurality of diffusion sensitizing gradient matrices are obtained and processed to determine a second order mean diffusion tensor and a fourth order covariance tensor. Quantities derived from these tensors are measured and mapped within an imaging volume which describe features of diffusion anisotropy and heterogeneity within each imaging voxel.
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
G01R 33/24 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance for measuring direction or magnitude of magnetic fields or magnetic flux
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Vizcardo, Raul E.
Islam, Sm Rafiqul
Tamaoki, Naritaka
Maeda, Takuya
Restifo, Nicholas P.
Abstract
Disclosed are methods for reprogramming cancer-reactive T cells into iPSC cells as well as methods utilizing such cells for the identification of cancer-antigen specific TCRs and the treatment of cancer.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Levin, Noam
Lowery, Iii, Frank J.
Parkhurst, Maria R.
Rosenberg, Steven A.
Abstract
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine. The TCRs may recognize G12V RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Henderson, Mark J.
Ronzetti, Michael H.
Baljinnyam, Bolormaa
Sanchez, Tino W.
Michael, Samuel G.
Owens, Ashley E.
Simeonov, Anton
Abstract
The disclosure provides methods for carrying out Real Time Cellular Thermal Shift Assays (RT-CETSA). Also provided are molecular constructs and protein constructs for use in such assays and devices suitable for carrying out such assays.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Lowery, Iii, Frank J.
Krishna, Sri
Robbins, Paul F.
Rosenberg, Steven A.
Altan-Bonnet, Gregoire Y.
Abstract
Disclosed are methods of obtaining a cell population enriched for T cells with a phenotype, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample of a patient; (b) specifically selecting T cells with a phenotype comprising markers CD3+, CD39−, and CD69− from the bulk population; and (c) separating the cells selected in (b) from cells which lack the phenotype to obtain a cell population enriched for T cells with the phenotype. Related methods of treating or preventing cancer, methods of selecting a therapy for a cancer patient, and methods for predicting the clinical response to immunotherapy in a cancer patient are also disclosed. Isolated or purified cell population obtained according to the methods and related pharmaceutical compositions are also disclosed.
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
28.
BROADLY NEUTRALIZING AND POTENT ANTIBODIES AGAINST HIV
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Appella, Daniel H.
Zheng, Hongchao
Amarasekara, Harsha C.
Clausse, Victor
Kubi, George A.
Abstract
Disclosed are thyclotides, which are oligomers, each comprising (a) from about 8 to about 25 monomer units of formula (I) and (b) from 0 to about 24 monomer units of formula (II): wherein B is a nucleobase, which can be the same or different at each occurrence, or a pharmaceutically acceptable salt thereof. The thyclotides are soluble in water, bind strongly to complementary DNA and RNA, and are cell permeable. The thyclotides are useful as reagents for antisense and antigene applications, and as probes in molecular diagnostics and microarrays.
C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
30.
METHOD OF ACHIEVING HIV VIRAL REMISSION USING LONG-ACTING ANTIRETROVIRAL AGENTS
The United State of America, as represented by Th Secretary, Department of Health and Human Services (USA)
Inventor
Daly, Michele B.
Garcia Lerma, Jose Gerardo
Heneine, Walid M.
Spreen, William Robert
Williams, Peter Evan Owen
Abstract
A method of achieving HIV viral remission in a patient in need thereof, comprising the steps of:
after exposure of the patient to the HIV virus, administering an early antiretroviral therapy (eART) of therapeutically effective amounts of cabotegravir and rilpivirine long-acting antiretrovirals, and
after eART suppression of the virus, discontinuing said early antiretroviral therapy.
C07D 231/06 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Collins, Peter L.
Le Nouen, Cyril
Buchholz, Ursula J.
Abstract
Provided is a polynucleotide encoding a respiratory syncytial virus (RSV) variant having an attenuated phenotype comprising a modified RSV genome or antigenome that encodes a mutant RSV protein P that differs from a parental RSV protein P at one or more amino acid residues. In some embodiments, the polynucleotide is recombinant. The invention also relates to methods of vaccinating an animal with the RSV variant or a pharmaceutical composition containing the RSV variant or inducing an immune response by administering the RSV variant to an animal, and further relates to methods of producing an RSV variant vaccine. In some embodiments, the animal is a human.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Yoseph, Rami
Copeland, Amy R.
Krishna, Sri
Lowery, Iii, Frank J.
Rosenberg, Steven A.
Robbins, Paul F.
Abstract
Provided are methods of preparing an enriched population of T cells having antigenic specificity for a target antigen. The method may comprise isolating T cells from a blood sample of a patient; selecting the isolated T cells which have a gene expression profile; and separating the selected T cells from the unselected cells. The separated selected T cells provide an enriched population of T cells having antigenic specificity for the target antigen. Methods of isolating a TCR, preparing a population of cells that express a TCR, isolated TCRs, isolated populations of cells, pharmaceutical compositions, and methods of treating or preventing a condition in a mammal are also provided.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
34.
APPLICATION OF AAV44.9 VECTOR IN GENE THERAPY FOR THE INNER EAR
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Consiglio Nazionale Delle Ricerche (Italy)
Inventor
Chiorini, John A.
Di Pasquale, Giovanni
Mammano, Fabio
Zorzi, Veronica
Abstract
Provided are methods of transducing hair cells of the inner ear in a subject comprising administering to the subject an adeno-associated viral (AAV) vector comprising a nucleic acid sequence encoding a capsid comprising the amino acid sequence of SEQ ID NO: 1, wherein the AAV vector further comprises a heterologous nucleic acid sequence. Additionally, methods of treating, preventing, or inhibiting a cochlear disorder or balance disorder in a subject comprising administering the AAV vector to the subject are provided.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Lu, Hanbing
Meng, Qinglei
Nguyen, Hieu
Yang, Yihong
Abstract
A system for administering transcranial magnetic stimulation to a subject is provided. The system includes a coil a controller, and a high-power switching module. The controller is configured to generate low voltage control signals for administering a treatment protocol via the coil. The high-power switching module is configured to generate a high voltage current delivered to the coil based on the low voltage control signals. In some embodiments, the high-power switching module includes a printed circuit board used to reduce intrinsic resistance and parasitic capacitance of the circuit such that the current delivered to the coil over a sequence of bursts remains stable. A new protocol for administering transcranial magnetic stimulation, referred to as high-density Theta Burst Stimulation (hdTBS), utilizes a pulse frequency of at least 40 Hz and a number of pulses per burst of four or greater.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Li, Lina
Kotin, Robert
Abstract
Closed-ended, linear, duplex (CELiD) DNA molecules, recombinant AAV (rAAV), particles comprising CELiD DNA, methods of making such molecules and particles, and therapeutic applications of such particles.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Levin, Noam
Yoseph, Rami
Paria, Biman C.
Rosenberg, Steven A.
Abstract
Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Bot, Adrian
Wiezorek, Jeffrey
Go, William
Jain, Rajul
Kochenderfer, James N.
Rosenberg, Steven A.
Abstract
The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
39.
USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES (2-D CELLS AND 3-D TISSUES) FOR USE IN CELL THERAPY AND TISSUE ENGINEERED PRODUCTS
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Bharti, Kapil
Hotaling, Nathan A.
Schaub, Nicholas J.
Simon, Carl G.
Abstract
A method is provided for non-invasively predicting characteristics of one or more cells and cell derivatives. The method includes training a machine learning model using at least one of a plurality of training cell images representing a plurality of cells and data identifying characteristics for the plurality of cells. The method further includes receiving at least one test cell image representing at least one test cell being evaluated, the at least one test cell image being acquired noninvasively and based on absorbance as an absolute measure of light, and providing the at least one test cell image to the trained machine learning model. Using machine learning based on the trained machine learning model, characteristics of the at least one test cell are predicted. The method further includes generating, by the trained machine learning model, release criteria for clinical preparations of cells based on the predicted characteristics of the at least one test cell.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Georgia Tech Research Corporation (USA)
Inventor
Gryder, Berkley E.
Oyelere, Adegboyega K.
Tapadar, Subhasish
Strope, Jonathan D.
Figg, Sr., William Douglas
Abstract
Disclosed is a compound of formula (I) in which R1, R2, R3, X1, X2, X2′, X3, X4, ring A, m, n, and o are as described herein. The compound of formula (I) is useful for treating a disorder associated with androgen receptor malfunction, such as a hyperproliferative disorder, in a subject in need thereof.
Disclosed is a compound of formula (I) in which R1, R2, R3, X1, X2, X2′, X3, X4, ring A, m, n, and o are as described herein. The compound of formula (I) is useful for treating a disorder associated with androgen receptor malfunction, such as a hyperproliferative disorder, in a subject in need thereof.
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
41.
Methods of preparing anti-human papillomavirus antigen T cells
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Hinrichs, Christian S.
Rosenberg, Steven A.
Abstract
Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Krishna, Sri
Lowery, Iii, Frank J.
Hanada, Ken-Ichi
Yang, James C.
Rosenberg, Steven A.
Robbins, Paul F.
Yoseph, Rami
Abstract
Provided are methods of preparing an enriched population of T cells having antigenic specificity for a target antigen. The method may comprise isolating T cells from a tumor sample of a patient; selecting the isolated T cells which have a gene expression profile; and separating the selected T cells from the unselected cells. The separated selected T cells provide an enriched population of T cells having antigenic specificity for the target antigen. Methods of isolating a T cell receptor (TCR), preparing a population of cells that express a TCR, isolated TCRs, isolated populations of cells, pharmaceutical compositions, and methods of treating or preventing a condition in a mammal are also provided.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
43.
Methods for the detection of cervical cancer and cervical intraepithelial neoplasia
The United States of America, as Represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Zheng, Zhi-Ming
Xu, Junfen
Zhu, Jun
Yang, Yanqin
Wang, Xiaohong
Abstract
Described herein are biomarkers for HPV-associated pre-cancers and cancers such as cervical cancer and cervical intraepithelial neoplasia. The RNA binding protein (RBP) and long-noncoding RNA (lnc-RNA) biomarkers can be detected and used to diagnose HPV-associated pre-cancers and cancers. In addition, early diagnosis of HPV-associated pre-cancers and cancers can facilitate therapeutic intervention in patients, particularly in the pre-cancer stage which can delay or prevent progression to cancer.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
44.
ANTIBACTERIAL AND ANTIFUNGAL POLYKETIDES FROM ENVIRONMENTAL AMYCOLATOPSIS SPP
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Bewley Clore, Carole A.
Liu, Hongbing
Ohlemacher, Shannon I.
Abstract
Disclosed are compounds represented by the formula:(I), wherein R is as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are a method of treating a subject in need of treatment for a bacterial infection or a fungal infection, which includes administering to the subject an effective amount of one of the compounds or salts thereof. Further disclosed is a process for producing the compounds and salts thereof.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
C12P 19/58 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound through only acyclic carbon atoms to a non-saccharide heterocyclic ring, e.g. bleomycin, phleomycin
45.
T CELL RECEPTORS RECOGNIZING MHC CLASS II-RESTRICTED MAGE-A3
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Robbins, Paul F.
Rosenberg, Steven A.
Yao, Xin
Abstract
The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
46.
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Levin, Noam
Yoseph, Rami
Paria, Biman
Rosenberg, Steven A.
Abstract
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
The United States of America, as Represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Yang, Shyh Ming
Maloney, David J.
Martinez, Natalia
Yasgar, Adam
Simeonov, Anton
Abstract
4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis. The disclosure also includes pharmaceutical compositions containing a compound or salt of Formula I.
C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
C07D 215/54 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
48.
HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Levin, Noam
Parkhurst, Maria R.
Lowery, Iii, Frank J.
Rosenberg, Steven A.
Abstract
Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Appella, Daniel H.
Nikolayevskiy, Herman
Robello, Marco
Scerba, Michael T.
Abstract
Disclosed is a compound of formula (I): for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.
Disclosed is a compound of formula (I): for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.
C07D 233/92 - Nitro radicals attached in position 4 or 5
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Singec, Ilyas
Jovanovic, Vukasin
Simeonov, Anton
Abstract
Methods for generating multipotent radial glia-like cells and astrocyte-like cells from human pluripotent stem cells are provided along with the related compositions.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Good, Meghan L.
Islam, Rafiqul Sm
Tamaoki, Naritaka
Vizcardo, Raul E.
Restifo, Nicholas P.
Abstract
Provided are methods of producing an isolated population of T cells for adoptive cell therapy. Also provided are related isolated populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer, infections, and autoimmune conditions in a patient.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Yoseph, Rami
Lu, Yong-Chen
Cafri, Gal
Rosenberg, Steven A.
Abstract
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Basser, Peter J.
Benjamini, Dan H.
Abstract
Multi-dimensional spectra associated with a specimen are reconstructed using lower dimensional spectra as constraints. For example, a two-dimensional spectrum associated with diffusivity and spin-lattice relaxation time is obtained using one-dimensional spectra associated with diffusivity and spin-lattice relaxation time, respectively, as constraints. Data for a full two dimensional spectrum are not acquired, leading to significantly reduced data acquisition times.
G01R 33/465 - NMR spectroscopy applied to biological material, e.g. in vitro testing
G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
54.
Coronary sinus mitral valve annuloplasty procedure and coronary artery and myocardial protection device
The United States of America, As Represented By The Secretary, Department of Health and Human Services (USA)
Inventor
Kim, June-Hong
Lederman, Robert J.
Kocaturk, Ozgur
Abstract
Devices and methods are disclosed for the treatment or repair of regurgitant cardiac valves, such as a mitral valve. An annuloplasty device can be placed in the coronary sinus to reshape the mitral valve and reduce mitral valve regurgitation. A protective device can be placed between the annuloplasty device and an underlying coronary artery to inhibit compression of the underlying coronary artery by the annuloplasty device in the coronary sinus. In addition, the protective device can inhibit compression of the coronary artery from inside the heart, such as from a prosthetic mitral valve that exerts radially outward pressure toward the coronary artery. The annuloplasty device can also create an artificial inner ridge or retaining feature projecting into the native mitral valve region to help secure a prosthetic mitral valve.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Khan, Javed
Hawley, Robert G.
Woldemichael, Girma M.
Peach, Megan L.
Abstract
The invention provides methods and compositions involving the compounds N′-(3,5-dimethylbenzoyl)picolinohydrazide; N′-(pyridin-2-yl)picolinohydrazide or pharmaceutically acceptable salts thereof for inhibiting the function of histone demethylases in vivo and in vitro, as well as methods for treating cancer comprising the administration of such compositions.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Kochenderfer, James N.
Abstract
The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
57.
Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Thompson, Scott
Van Dyke, Adam
Thomas, Craig
Morris, Patrick
Abstract
A receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Hanada, Kenichi
Wang, Qiong J.
Yang, James C.
Yu, Zhiya
Abstract
Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
De Los Pinos, Elisabet
Schiller, John Todd
Kines, Rhonda C.
Macdougall, John
Abstract
The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Wohlstadter, Jacob N.
Sigal, George
Wilbur, James
Debad, Jeffery
Biebuyck, Hans
Krai, Priscilla
Kishbaugh, Alan
Dzantiev, Leonid
Shelburne, Christopher
Campbell, Christopher
Aksyuk, Anastasia
Mcdermott, Adrian
O'Connell, Sarah
Narpala, Sandeep
Lin, Chien Li
Abstract
The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention further provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Ho, Mitchell
Wang, Ruixue
St. Croix, Brad
Li, Dan
Abstract
Single-domain monoclonal antibodies that specifically bind B7H3 (also known as CD276) are described. The single-domain antibodies include camel VHH and rabbit VH domain nanobodies selected from phage display libraries. Chimeric antigen receptors (CARs) and other antibody conjugates targeted to B7H3 are also described. The single-domain antibodies and conjugates thereof can be used for the diagnosis and treatment of B7H3 expressing solid tumors.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Hinrichs, Christian S.
Rosenberg, Steven A.
Abstract
Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
Skolkovo Institute of Science and Technology (Russia)
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Severinov, Konstantin
Zhang, Feng
Wolf, Yuri I.
Shmakov, Sergey
Semenova, Ekaterina
Minakhin, Leonid
Makarova, Kira S.
Koonin, Eugene
Konermann, Silvana
Joung, Julia
Gootenberg, Jonathan S.
Abudayyeh, Omar O.
Lander, Eric S.
Abstract
The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Florida State University Research Foundation, Inc. (USA)
The Trustees of the University of Pennsylvania (USA)
Inventor
Tang, Hengli
Lee, Emily M.
Zheng, Wei
Huang, Ruili
Xu, Miao
Huang, Wenwei
Shamim, Khalida
Ming, Guoli
Song, Hongjun
Abstract
The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/4741 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
65.
Methods and systems for Maxwell compensation for spin-echo train imaging
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Mugler, Iii, John P.
Meyer, Craig H.
Campbell, Adrienne
Ramasawmy, Rajiv
Pfeuffer, Josef
Wang, Zhixing
Feng, Xue
Abstract
Methods, computing devices, and MRI systems that reduce artifacts produced by Maxwell gradient terms in TSE imaging using non-rectilinear trajectories are disclosed. With this technology, a RF excitation pulse is generated to produce transverse magnetization that generates a NMR signal and a series of RF refocusing pulses to produce a corresponding series of NMR spin-echo signals. An original encoding gradient waveform comprising a non-rectilinear trajectory is modified by adjusting a portion of the original encoding gradient waveform or introducing a zero zeroth-moment waveform segment at end(s) of the original encoding gradient waveform. During an interval adjacent to each of the series of RF refocusing pulses a first gradient pulse is generated. At least one of the first gradient pulses is generated according to the modified gradient waveform. An image is constructed from generated digitized samples of the NMR spin-echo signals obtained.
G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
66.
Systems and methods for three-dimensional fluorescence polarization via multiview imaging
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE UNIVERSITY OF CHICAGO (USA)
THE MARINE BIOLOGICAL LABORATORY (USA)
Inventor
Shroff, Hari
Kumar, Abhishek
Mehta, Shalin B.
La Riviere, Patrick Jean
Oldenbourg, Rudolf
Wu, Yicong
Chandler, Talon
Abstract
Systems and methods for three-dimensional fluorescence polarization excitation that generates maps of positions and orientation of fluorescent molecules in three or more dimensions are disclosed.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Egwuagu, Charles E.
Choi, Jin Kyeong
Abstract
The invention is directed to an isolated population of mammal cells comprising about 75% or higher B-1a regula e PBS-treated tory cells expressing the cell surface inhibitory receptors lympho-cyte-activation gene 3 (LAG-3), programmed cell death protein 1 (PD-1), and C-X-C chemokine receptor type 4 (CXCR4), and secreting interleukin-27 (IL-27). The invention is also directed to methods of preparing and using the cell population to suppress the immune system and/or to treat or prevent diseases.
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Boyington, Jeffrey C.
Graham, Barney S.
Mascola, John R.
Yassine, Hadi M.
Corbett, Kizzmekia S.
Moin, Syed M.
Wang, Lingshu
Kanekiyo, Masaru
Abstract
Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Bharti, Kapil
Barbosa Sabanero, Karla Yadira
Chang, Justin Ren Yuan
Jha, Balendu Shekhar
Sharma, Ruchi
Abstract
This invention relates to novel method of treating or ameliorating a retinal disease or disorder or retinal degradation in a subject and a novel method of restoring retinal pigment epithelium cell compromising the administration of a one or more compounds which modulate Nox4, formation of radical oxygen species, serine protease, a dopamine receptor, NF-kB, mTOR, AMPK, RPE epithelial to mesenchymal transition, RPE dedifferentiation, or one or more Rho GTPases; and kits for administration of the methods.
FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, Inc. (USA)
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventor
Tang, Hengli
Lee, Emily M.
Zheng, Wei
Huang, Ruili
Xu, Miao
Huang, Wenwei
Shamim, Khalida
Ming, Guoli
Song, Hongjun
Abstract
The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/4741 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
71.
PROTEIN PANELS FOR THE EARLY DIAGNOSIS/PROGNOSIS AND TREATMENT OF AGGRESSIVE PROSTATE CANCER
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (USA)
THE UNITED STATES OF AMERICA,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Rodland, Karin
Liu, Tao
Cullen, Jennifer
Petrovics, Gyorgy
Kagan, Jacob
Srivastava, Sudhir
Abstract
Disclosed herein are methods of diagnosing or prognosing aggressive prostate cancer in a subject and methods of treating a subject with aggressive prostate cancer. For example, the methods can include measuring increased expression of aggressive prostate cancer-related molecules (such as FOLH1, SPARC, TGFB1, CAMKK2, NCOA2, EGFR, or PSA) and optionally administering a therapeutically effective amount of aggressive prostate cancer therapy.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Deniger, Drew C.
Malekzadeh, Parisa
Rosenberg, Steven A.
Pasetto, Anna
Abstract
Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53R175H or human p53Y220C. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Leonard, Warren J.
Hermans, Dalton J.
Gattinoni, Luca
Neckers, Leonard M.
Gautam, Sanjivan
Abstract
The invention provides compositions and methods for using adoptive cell therapy (ACT) for treating cancer in a mammal. Cultured T-cells are provided by (a) obtaining an isolated population of T cells, and (b) culturing the isolated T cells ex vivo in the presence of a cytokine and a lactate dehydrogenase inhibitor. The cultured T-cells then can be administered to the mammal
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Venditti, Charles P.
Chandler, Randy J.
Abstract
Synthetic polynucleotides encoding human propionyl-CoA carboxylase beta (synPCCB) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synPCCB successfully rescued the neonatal lethal phenotype displayed by propionyl-CoA carboxylase beta (Pccb−/−) deficient mice, lowered circulating methylcitrate levels in the treated animals, and resulted in prolonged hepatic expression of the product of the synPCCB transgene in vivo.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
University of Louisville Research Foundation, Inc. (USA)
University of Pittsburgh - Of the Commonwealth System of Higher Education (USA)
Inventor
O'Keefe, Barry R.
Moulaei, Tinoush
Palmer, Kenneth E.
Rohan, Lisa C.
Fuqua, Joshua L.
Kramzer, Lindsay F.
Abstract
The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Schlom, Jeffrey
Palena, Claudia M.
Abstract
Brachyury protein can be used to induce Brachyury-specific CD4+ T cells in vivo and ex vivo. It is also disclosed that Brachyury protein can be used to stimulate the production of both Brachyury-specific CD4+ T cells and Brachyury-specific CD8+ T cells in a subject, such as a subject with cancer. In some embodiments, the methods include the administration of a Brachyury protein. In additional embodiments, the methods include the administration of a nucleic acid encoding the Brachyury protein, such as in a non-pox non-yeast vector. In further embodiments, the methods include the administration of host cells expressing the Brachyury protein.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Korinek, William S.
Lechleiter, James D.
Liston, Theodore E.
Jacobson, Kenneth A.
Abstract
The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61P 25/00 - Drugs for disorders of the nervous system
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Nieman, Lynnette K.
Ullman, Andre
Newman, Arnold L.
Abstract
A method of ameliorating a disorder of insulin sensitivity, which entails administering an amount of one or more glucocorticoid receptor antagonists effective to ameliorate the disorder with no more than an acceptable activation of the hypothalamic-pituitary-adrenal axis, such that 24 hour serum or urine cortisol levels do not exceed about two to three times the upper normal limit, respectively.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Palmer, Douglas C.
Pasetto, Anna
Restifo, Nicholas P.
Rosenberg, Steven A.
Abstract
Provided are methods of producing an isolated population of cells for adoptive cell therapy comprising use of at least one cell permeable Ca2+ dye. Further embodiments of the invention provide isolated populations of cells produced by the methods, related pharmaceutical compositions, and related methods of treating or preventing cancer in a patient.
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
University of Strathelyde (United Kingdom)
Inventor
Atreya, Chintamani
Maclean, Michelle
Anderson, John G.
Macgregor, Scott J.
Abstract
Disclosed herein are methods and devices for the inactivation of pathogens (e.g., bacteria, viruses, etc.) in ex vivo stored blood products, such as plasma and/or platelets, by means of directing visible light radiation from an illuminating device into blood product storage containers in order to achieve effective pathogen inactivation without the presence of an added photosensitising agent in the blood product. An exemplary apparatus includes a control unit that operates a light source that emits light in the wavelength region of about 380-500 nm which is directed onto blood product storage bags at sufficient intensity to penetrate the bag material and the opaque blood product therein in order to inactivate pathogens in the blood product but at dose levels that cause no significant detrimental effects on the blood product.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Reich, Daniel Salo
Beck, Erin Savner
Nair, Govind
Gai, Neville Dali
Abstract
Provided herein are methods and systems for high-resolution, cerebrospinal fluid-suppressed T2*-weighted magnetic resonance imaging of cortical lesions.
G01V 3/00 - Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination or deviation
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
82.
SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Venditti, Charles P.
Chandler, Randy J.
Abstract
Synthetic polynucleotides encoding human propionyl-CoA carboxylase alpha (synPCCA) and exhibiting augmented expression in cell culture and/or in a subject are described herein. Adeno-associated viral (AAV) gene therapy vectors encoding synPCCA successfully rescued the neonatal lethal phenotype displayed by propionyl-CoA carboxylase alpha (Pcca−/−) deficient mice, lowered circulating methylcitrate levels in the treated animals, and resulted in prolonged hepatic expression of the product of the synPCCA transgene in vivo.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Singec, Ilyas
Deng, Tao
Simeonov, Anton
Abstract
Methods for Generating Neural Crest-Like Cells and Nociceptor-Like Cells from Human Pluripotent Stem Cells are Provided Along with the Related Compositions.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Seder, Robert
Wang, Lawrence
Vistein, Rachel
Francica, Joseph
Abstract
Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Alimardanov, Asaf Ragim
Huang, Junfeng
Abstract
A process for the preparation of racemic and optically active (1E,NE)-N-(1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N′-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide in high enantiomerical purity is provided.
C07D 231/06 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
86.
Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
VANDERBILT UNIVERSITY (USA)
THE UAB RESEARCH FOUNDATION (USA)
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventor
Maloney, David J.
Waterson, Alex Gregory
Bantukallu, Ganesh Rai
Brimacombe, Kyle Ryan
Christov, Plamen
Dang, Chi V.
Darley-Usmar, Victor
Hu, Xin
Jadhav, Ajit
Jana, Somnath
Kim, Kwangho
Kouznetsova, Jennifer L.
Moore, William J.
Mott, Bryan T.
Neckers, Leonard M.
Simeonov, Anton
Sulikowski, Gary Allen
Urban, Daniel Jason
Yang, Shyh Ming
Abstract
Provided is a compound of formula (I)
1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Kochenderfer, James N.
Abstract
The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Cafri, Gal
Robbins, Paul F.
Rosenberg, Steven A.
Abstract
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Robbins, Paul F.
Rosenberg, Steven A.
Zhu, Shiqui
Feldman, Steven A.
Morgan, Richard A.
Abstract
The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Shapiro, Bruce A.
Zakrevsky, Paul J.
Abstract
Disclosed are DNA/RNA hybrid nucleic acid nanoparticles comprising at least one trigger toehold or at least one exchange toehold, wherein each at least one trigger toehold and the at least one exchange toehold independently comprise DNA and/or RNA, and at least one single stranded RNA output strand, wherein no portion of the at least one trigger toehold hybridizes to any portion of the at least one output strand, the at least one trigger toehold is complementary and hybridizes to a first target sequence when the nanoparticle is in the presence of the first target sequence, and the nanoparticle does not contain the target sequence. Related pharmaceutical compositions, methods of treating a patient with a disease or condition, and methods of diagnosing a patient with a disease or condition are also disclosed.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Remaley, Alan T.
Neufeld, Edward B.
Sato, Masaki
Abstract
A method of assessing the risk for development of cardiovascular disease (CVD) or an inflammatory disease in a patient comprises (i) incubating a sample of body fluid with donor particles, wherein the donor particles are coated with a lipid and a first quantity of detectably labeled, non-exchangeable lipid probe (NELP); (ii) separating the detectably labeled NELP-associated HDL into a first portion and the donor particles into a second portion; (iii) measuring the second quantity of detectably labeled NELP in the first portion; (iv) determining a detectably labeled NELP efflux value for the patient; and (v) comparing the detectably labeled NELP efflux value for the patient to a reference standard. Related methods of lowering the risk for development of CVD or an inflammatory disease in a patient and methods of measuring the quantity of functional HDL in a sample of body fluid are also provided.
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Remaley, Alan T.
Gordon, Scott M.
Abstract
Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as A1AT-peptide-enriched HDL particles, and their use in various therapeutic contexts.
A61K 38/58 - Protease inhibitors from humans from leeches, e.g. hirudin, eglin
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Seder, Robert
Lynn, Geoffrey
Abstract
Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Kochenderfer, James N.
Abstract
The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. (USA)
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Campbell, Christopher
Kenney, Kimbra
Gill, Jessica
Abstract
The invention relates to methods and kits for assessing brain injury, e.g., traumatic brain injury resulting from blast exposure. The invention provides methods of quantifying the amount of phosphorylated tau or total tau in a biological sample. The invention further provides a method of determining the number of blast exposures experienced by a subject. Also provided herein are kits for detecting phosphorylated tau or total tau in a biological sample.
GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Kaplan, Rosandra N.
Kratzmeier, Sabina A.
Beury, Daniel W.
Qin, Haiying
Abstract
Provided are compositions comprising genetically modified hematopoietic stem and progenitor cells (HSPCs) and/or genetically modified mesenchymal cells, wherein the cells contain a vector comprising a transgene, as well as methods of producing the genetically modified HSPCs and genetically modified mesenchymal cells, and methods of treating or preventing cancer (e.g., metastasis) and neurodegenerative conditions, autoimmune disorders, and inflammatory disorders.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Sato, Noriko
Wu, Haitao
Griffiths, Gary L.
Choyke, Peter L.
Abstract
The invention provides a method of preparing a 89Zr-oxine complex of the formula
The invention provides a method of preparing a 89Zr-oxine complex of the formula
The invention provides a method of preparing a 89Zr-oxine complex of the formula
The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic System
G01N 33/60 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C12Q 1/16 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor using radioactive material
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
99.
Antibodies and methods for the diagnosis and treatment of Epstein Barr Virus infection
The United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (USA)
Inventor
Bu, Wei
Kanekiyo, Masaru
Joyce, Michael Gordon
Cohen, Jeffrey I.
Abstract
Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
The United States of America,as Represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Ho, Mitchell
Li, Nan
Pan, Jiajia
Abstract
Monoclonal antibodies that specifically bind glypican-1 (GPC1) are described. Chimeric antigen receptor (CAR) T cells, immunotoxins and other antibody conjugates based on the GPC1-specific antibodies are also described. The disclosed CAR T cells, immunotoxins, GPC1-specific antibodies and conjugates thereof can be used, for example, in the diagnosis or treatment of GPC1-positive pancreatic cancer and other cancers.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment